Fagron NV (FAGR.BR) — Quality & forensics
As of 2026-10-28 — refreshed nightly. Closelooknet readings from an investment research diary, not ratings or advice.
The Closelooknet module scores
- Valuation 58
- Quality 56
- Growth 56
- Balance sheet 53
- Cash quality 39
- Capital allocation 52
- Momentum 57
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the grey zone (1.81–2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.
Continue: the FAGR.BR chart & overview
FAQ · from the current data · as of 2026-10-28
Quick answers
What is Fagron NV's Closelooknet quality reading?
The composite reads 54/100 across 7 modules, as of 2026-10-28: valuation 58, quality 56, growth 56, balance sheet 53, cash quality 39, capital allocation 52, momentum 57. Closelooknet scores are research diary readings, not ratings or investment advice.
What is Fagron NV's Altman Z-Score?
2.84, which sits in the grey zone (1.81–2.99) as of 2026-10-28. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is Fagron NV's Piotroski F-Score?
5 of 9, as of 2026-10-28. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does Fagron NV's Beneish M-Score indicate?
-1.90 — below the −1.78 manipulation-risk threshold, as of 2026-10-28. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Related in the Closelooknet universe
then Drug Manufacturers - Specialty & Generic. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- ROVI.MC Laboratorios Farmaceuticos ROVIindustry
- BHC.TO Bausch Health Companies Incindustry
- AMRX Amneal Pharmaceuticals, Inc. Class A Common Stockindustry
- GALDY GALDERMA GROUP AGindustry
- IRWD Ironwood Pharmaceuticals Incindustry
- ALM.MC Almirall S.A.industry
- PCRX Pacira BioSciences, Inc.industry
- KNSA Kiniksa Pharmaceuticals Ltdindustry
- HLUN-B.CO H Lundbeck A/Sindustry
- XERS Xeris Pharmaceuticals Incindustry
- UTHR United Therapeutics Corporationindustry
- GUD.TO Knight Therapeutics Inc.industry
- PRGO Perrigo Company PLCindustry
- VTRS Viatris Incindustry
- AMPH Amphastar Pindustry
- VETO.PA Vetoquinolindustry
- 000538.SHE Yunnan Baiyao Group Co Ltdindustry
- FAE.MC Faes Farma SAindustry
- CRON Cronos Group Incindustry
- DHT-UN.TO DRI Healthcare Trustindustry